Ad
Tuesday, 14 April 2020
AstraZeneca to test impact of cancer drug Calquence on coronavirus patients
AstraZeneca Plc said on Tuesday it would start a clinical trial of its cancer drug Calquence to assess its potential to control the exaggerated immune system response associated with COVID-19 infection in severely ill patients.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment